The combination of an EZH2 inhibitor with nilotinib was found to potentiate the capacity of each single agent to eradicate CML CD34+ cells in a xenograft mouse model while sparing normal stem cells49. Here, EZH2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.